BIOMAT Database Logo BIOMAT Database Logo

[Absorption and excretion, and clinical study of sustained release cephalexin (S-6437) in children (author's transl)]. 1977

T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011511 Proteus A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in the intestines of humans and a wide variety of animals, as well as in manure, soil, and polluted waters. Its species are pathogenic, causing urinary tract infections and are also considered secondary invaders, causing septic lesions at other sites of the body.
D011704 Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA. Necrotizing Pyelonephritis,Pyelonephritis, Acute Necrotizing,Pyelonephritides
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Study of S-6437 (sustained release cephalexin) in pediatrics (author's transl)].
September 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Study of S-6437, sustained release cephalexin, in pediatrics (author's transl)].
September 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical study of sustained release cephalexin (S-6436, S-6437) in dermatology (author's transl)].
November 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical experience with sustained release cephalexin (S-6437) in pediatrics (author's transl)].
February 1978, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Studies of sustained release cephalexin (S-6437) in pediatrics (author's transl)].
September 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical experience with sustained release cephalexin (X-6437) (author's transl)].
November 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical experience with sustained release cephalexin (S-6436) in urology (author's transl)].
November 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical study of sustained release cephalexin (S-6435 and S-6436) in tonsillitis and pharyngitis (author's transl)].
November 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical experience with sustained release cefalexin (S-6437) for pediatric use in pediatrics (author's transl)].
November 1977, The Japanese journal of antibiotics,
T Motohiro, and Y Sakata, and T Nishiyama, and T Nakajima, and K Ishimoto, and K Tominaga, and F Yamashita
[Clinical study of S-6437 in pediatrics (author's transl)].
September 1977, The Japanese journal of antibiotics,
Copied contents to your clipboard!